WHO Drug Information Vol. 18, No. 1, 2004
(2004; 109 pages) View the PDF document
Table of Contents
Open this folder and view contentsRegulatory Challenges
Open this folder and view contentsEssential Medicines
Open this folder and view contentsSafety and Efficacy Issues
Open this folder and view contentsVaccines and Biomedicines
Open this folder and view contentsHerbal Medicines
Close this folderRegulatory and Safety Action
View the documentNevirapine and hepatotoxicity
View the documentAntidepressants in adults and children
View the documentRecommended influenza vaccines: 2004-2005
View the documentOlanzapine and cerebrovascular events
View the documentOlanzapine: hyperglycaemia and diabetes
View the documentBetter labelling for ingredient sensitivities
Open this folder and view contentsConsultation Document
View the documentProposed International Nonproprietary Names: List 90
View the documentRecommended International Nonproprietary Names: List 51
 

Recommended influenza vaccines: 2004-2005

World Health Organization - The composition of influenza vaccines for the Northern hemisphere 2004-2005 Winter season has been determined as follows:

• an A/New Caledonia/20/99(H1N1)-like virus

• an A/Fjian/411/2002(H3N2)-like virus. (The currently used vaccine virus is A/Wyoming/3/ 2003 A/Kumamoto/102/2002 is also available.)

• a B/Shanghai/361/2002-like virus. (Candidate vaccine viruses include B/Shanghai/361/2002 and B/Jilin/20/2003.)


The national control authorities should approve the specific vaccine viruses used in each country. National public health authorities are responsible for recommendations regarding use of the vaccine. Updated epidemiological information is available on WHO’s website at http://who.int/ influenza.

Reference: Weekly Epidemiological Record, 79: 91 (2004)

to previous section to next section
 

Last updated: May 3, 2013